1 国家卫生健康委员会,国家中医药管理局.新型冠状病毒肺炎诊疗方案(试行第六版)的通知[EB/OL].[2020-02-19].http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5474791.htm. 2 Liang WH,Guan WJ,Chen RC,et al.Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China[J].Lancet Oncology,2020,21(3):335-337. 3 徐骏,耿美玉,黄敏.化疗药调控肿瘤免疫应答机制研究进展[J].药学学报,2019,54(10):1741-1748. 4 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中国实用外科杂志,2020,40(2):121-138. 5 梁后杰,秦叔逵,沈锋,等.CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J].临床肿瘤学杂志,2019,24(9):828-838. 6 刘梦奇,吉顺荣,徐晓武,等.2019年胰腺癌研究及诊疗新进展[J].中国癌症杂志,2020,30(1):1-10. 7 杨振宇,谭凯,杜锡林,等.新型冠状病毒疫情期间肿瘤患者的应急管理及防护措施[J].现代肿瘤医学,2020,28(6):1053-1055. 8 Vivaldi C,Fornaro L,Vasile E.FOLFIRINOX adjuvant therapy for pancreatic cancer[J].N Engl J Med,2019,380(12):1187-1188. 9 Weigt J,Malfertheiner P.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].Eepert Rev Gastroent,2010,4(4):395-397. 10 Valle J,Wasan H,Palmer DH,et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med,2010,362(14):1273-1281. 11 Michelakos T,Pergolini I,Castillo CF,et al.Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX[J].Ann Surg,2019,269(4):733-740. 12 Okada KI,Shimokawa T,Hirono S,et al.Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer:a prospective multicenter phase II Trial(NAC-GA Trial)[J].Oncology,2017,93(5):343-346. 13 Masui T,Doi R,Kawaguchi Y,et al.Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors[J].Surg Today,2016,46(11):1282-1289. 14 Kim YS,Jeong CY,Song HN,et al.The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection[J].Chin J Cancer,2017,36:1-9. 15 Uesaka K,Boku N,Fukutomi A,et al.Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer:a phase 3,open-label,randomised,non-inferiority trial(JASPAC 01)[J].Lancet,2016,388(10041):248-257. 16 Neoptolemos J,Stocken DD,Friess H,et al.A randomized trial of chemoradiotheray and chemotherapy after resection of pancreatic cancer[J].N Engl J Med,2016,350(12):1200-1210. 17 Neoptolemos JP,Palmer DH,Ghaneh P,et al.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer(ESPAC-4):a multicentre,open-label,randomised,phase 3 trial[J].Lancet,2017,389(10073):1011-1024. 18 Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J].N Engl J Med,2018,379(25):2395-2406. 19 Rimassa L,Danesi R,Pressiani T,et al.Management of adverse events associated with tyrosine kinase inhibitors:Improving outcomes for patients with hepatocellular carcinoma[J].Cancer Treat Rev,2019,77:20-28. 20 Junki M,Chigusa M,Takuji O,et al.Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer:Japan Clinical Oncology Group Study(JCOG1113,FUGA-BT)[J].Jpn J Clin Oncol,2016,46(4):385-388. 21 Pitt HA,Gomes AS,Lois JF,et al.Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?[J].Anna Surg,1985,201(5):545-553. 22 Nimura Y,Kamiya J,Kondo S,et al.Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma:Nagoya experience[J].J Hepatobiliary Pancreat Surg,2000,7(2):155-162. 23 易丹,杜梦楠,贾英杰.肿瘤患者在新型冠状病毒疫情期间如何规避风险[J].现代肿瘤医学,2020,28(7):1-3. |